PURPOSE: Published reports suggest that DNA microarrays identify clinically meaningful subtypes of lung adenocarcinomas not recognizable by other routine tests. This report is an investigation of the reproducibility of the reported tumor subtypes. METHODS: Three independent cohorts of patients with lung cancer were evaluated using a variety of DNA microarray assays. Using the integrative correlations method, a subset of genes was selected, the reliability of which was acceptable across the different DNA microarray platforms. Tumor subtypes were selected using consensus clustering and genes distinguishing subtypes were identified using the weighted difference statistic. Gene lists were compared across cohorts using centroids and gene set enrichment analysis. RESULTS: Cohorts of 31, 72, and 128 adenocarcinomas were generated for a total of 231 microarrays, each with 2,553 reliable genes. Three adenocarcinoma subtypes were identified in each cohort. These were named bronchioid, squamoid, and magnoid according to their respective correlations with gene expression patterns from histologically defined bronchioalveolar carcinoma, squamous cell carcinoma, and large-cell carcinoma. Tumor subtypes were distinguishable by many hundreds of genes, and lists generated in one cohort were predictive of tumor subtypes in the two other cohorts. Tumor subtypes correlated with clinically relevant covariates, including stage-specific survival and metastatic pattern. Most notably, bronchioid tumors were correlated with improved survival in early-stage disease, whereas squamoid tumors were associated with better survival in advanced disease. CONCLUSION: DNA microarray analysis of lung adenocarcinomas identified reproducible tumor subtypes which differ significantly in clinically important behaviors such as stage-specific survival.
PURPOSE: Published reports suggest that DNA microarrays identify clinically meaningful subtypes of lung adenocarcinomas not recognizable by other routine tests. This report is an investigation of the reproducibility of the reported tumor subtypes. METHODS: Three independent cohorts of patients with lung cancer were evaluated using a variety of DNA microarray assays. Using the integrative correlations method, a subset of genes was selected, the reliability of which was acceptable across the different DNA microarray platforms. Tumor subtypes were selected using consensus clustering and genes distinguishing subtypes were identified using the weighted difference statistic. Gene lists were compared across cohorts using centroids and gene set enrichment analysis. RESULTS: Cohorts of 31, 72, and 128 adenocarcinomas were generated for a total of 231 microarrays, each with 2,553 reliable genes. Three adenocarcinoma subtypes were identified in each cohort. These were named bronchioid, squamoid, and magnoid according to their respective correlations with gene expression patterns from histologically defined bronchioalveolar carcinoma, squamous cell carcinoma, and large-cell carcinoma. Tumor subtypes were distinguishable by many hundreds of genes, and lists generated in one cohort were predictive of tumor subtypes in the two other cohorts. Tumor subtypes correlated with clinically relevant covariates, including stage-specific survival and metastatic pattern. Most notably, bronchioid tumors were correlated with improved survival in early-stage disease, whereas squamoid tumors were associated with better survival in advanced disease. CONCLUSION: DNA microarray analysis of lung adenocarcinomas identified reproducible tumor subtypes which differ significantly in clinically important behaviors such as stage-specific survival.
Authors: Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; C Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh Thorne; Philip S Bernard; Charles M Perou; D Neil Hayes Journal: Clin Cancer Res Date: 2010-07-19 Impact factor: 12.531
Authors: Pablo Tamayo; Daniel Scanfeld; Benjamin L Ebert; Michael A Gillette; Charles W M Roberts; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2007-03-27 Impact factor: 11.205
Authors: Ajay P Singh; Sangeeta Bafna; Kunal Chaudhary; Ganesh Venkatraman; Lynette Smith; James D Eudy; Sonny L Johansson; Ming-Fong Lin; Surinder K Batra Journal: Cancer Lett Date: 2007-10-30 Impact factor: 8.679
Authors: Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: Anita K Mehta; Kevin Hua; William Whipple; Minh-Thuy Nguyen; Ching-Ti Liu; Johannes Haybaeck; Joanne Weidhaas; Jeff Settleman; Anurag Singh Journal: Sci Signal Date: 2017-09-12 Impact factor: 8.192